Next Article in Journal
Epigallocatechin-3-gallate Can Prevent Type 2 Human Papillomavirus E7 from Suppressing Interferon-Stimulated Genes
Next Article in Special Issue
Oncolytic Adenoviruses for Cancer Therapy
Previous Article in Journal
Insights into Interactions between Interleukin-6 and Dendritic Polyglycerols
Previous Article in Special Issue
High-Throughput Cloning and Characterization of Emerging Adenovirus Types 70, 73, 74, and 75
Review

Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors

Center for Biomedical Education and Research (ZBAF), Witten/Herdecke University (UW/H), Stockumer Str. 10, 58448 Witten, Germany
*
Authors to whom correspondence should be addressed.
Academic Editor: Ruben Hernandez-Alcoceba
Int. J. Mol. Sci. 2021, 22(5), 2417; https://doi.org/10.3390/ijms22052417
Received: 31 January 2021 / Revised: 24 February 2021 / Accepted: 24 February 2021 / Published: 28 February 2021
(This article belongs to the Special Issue Adenovirus: Enduring Toolbox for Basic and Applied Research)
Adenovirus-based gene transfer vectors are the most frequently used vector type in gene therapy clinical trials to date, and they play an important role as genetic vaccine candidates during the ongoing SARS-CoV-2 pandemic. Immediately upon delivery, adenovirus-based vectors exhibit multiple complex vector-host interactions and induce innate and adaptive immune responses. This can severely limit their safety and efficacy, particularly after delivery through the blood stream. In this review article we summarize two strategies to modulate Ad vector-induced immune responses: extensive genomic and chemical capsid modifications. Both strategies have shown beneficial effects in a number of preclinical studies while potential synergistic effects warrant further investigations. View Full-Text
Keywords: adenovirus; vector; PEGylation; HPMA; immune response; shielding; stealthing; cloaking adenovirus; vector; PEGylation; HPMA; immune response; shielding; stealthing; cloaking
Show Figures

Graphical abstract

MDPI and ACS Style

Kreppel, F.; Hagedorn, C. Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors. Int. J. Mol. Sci. 2021, 22, 2417. https://doi.org/10.3390/ijms22052417

AMA Style

Kreppel F, Hagedorn C. Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors. International Journal of Molecular Sciences. 2021; 22(5):2417. https://doi.org/10.3390/ijms22052417

Chicago/Turabian Style

Kreppel, Florian, and Claudia Hagedorn. 2021. "Capsid and Genome Modification Strategies to Reduce the Immunogenicity of Adenoviral Vectors" International Journal of Molecular Sciences 22, no. 5: 2417. https://doi.org/10.3390/ijms22052417

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop